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Objective: Skin graft donor site management is a concern particularly for el-
derly patients and patients with poor wound healing competence, and also
because donor sites are a source of pain and discomfort. Although different
types of dressings exist, there is no consensus regarding optimal dressing type
on donor site care to promote healing, reduce pain, and improve patients’
comfort.
Approach: This prospective, single-center clinical trial evaluated the perfor-
mance of nanofibrillar cellulose (NFC) wound dressing (FibDex by UPM-
Kymmene Corporation) for treatment of donor sites compared with a
polylactide-based copolymer dressing. The study enrolled 24 patients requir-
ing skin grafting with mean age of 49– 18. The primary outcome measure was
wound healing time. Secondary outcomes, the epithelialization, subjective
pain, the scar appearance assessed using the Patient and Observer Scar As-
sessment Scale (POSAS), and skin elasticity and transepidermal water loss
(TEWL), were evaluated at 1 and 6 months postoperatively.
Results: No statistically significant differences were observed between NFC
and copolymer dressings regarding wound healing time, epithelialization, ex-
perience of pain, or TEWL. Significant differences were observed in the POSAS
results for thickness and vascularity in the Observer score, in the favor of NFC
over copolymer dressing. Moreover, skin elasticity was significantly improved
with NFC dressing in terms of viscoelasticity and elastic modulus at 1 month
postoperatively.
Innovation: NFC dressing is a new, green sustainable product for wound
treatment without animal or human-origin components.
Conclusion: NFC dressing provides efficient wound healing at skin graft donor
sites and is comparable or even preferable compared with the copolymer dressing.
Keywords: nanofibrillar cellulose, wound dressing, skin graft donor site
treatment, patient, clinical study
Raili Koivuniemi, PhD
Submitted for publication April 23, 2019.
Accepted in revised form April 29, 2019.
*Correspondence: Drug Research Program,
Division of Pharmaceutical Biosciences, Faculty
of Pharmacy, University of Helsinki, P.O. Box 56,
Helsinki 00014, Finland
(e-mail: raili.koivuniemi@helsinki.fi).
ª Raili Koivuniemi, et al. 2019; Published by Mary Ann Liebert, Inc. This Open Access article is
distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
j 199ADVANCES IN WOUND CARE, VOLUME 9, NUMBER 4
Mary Ann Liebert, Inc. DOI: 10.1089/wound.2019.0982
INTRODUCTION
The management of the donor site after split-
thickness harvesting may be problematic due to
delayed healing, especially in elderly patients, due
to pain and discomfort at the donor site, or in pa-
tients with systemic comorbidities.1,2 A wide variety
of dressings are available but no widely approved
material exists for these wounds. Various dressings
raise issues regarding low absorption to exudate,
desiccation, frequent dressing changes, developing
resistance to microbes, or price.3 An ideal wound
dressing would promote re-epithelialization, provide
a moist environment, prevent growth of micro-
organisms, absorb exudate, and be transparent and
comfortable for the patient and cost-effective and
easy to apply.
Nanofibrillar cellulose (NFC) derived from wood
with nanoscale diameter and microscale length is
potentially a cost-efficient material to be used in
pharmaceutical or biomedical applications. Having
high aspect ratio, that is, a ratio of particle length to
width and high elastic modulus, NFC can be easily
modified into various forms, such as hydrogels,
films, and aerogels.4–6 These physical and mechan-
ical properties have made NFC useful as a drug and
cell carrier, or cell scaffold.7–10 Further, the poten-
tial of NFC for wound treatment applications has
recently been recognized based on its biocompati-
bility and ability to absorb and retain moisture.11–14
In comparison, bacterial cellulose (BC) and car-
boxymethyl cellulose (CMC) share many advanta-
geous wound healing properties with NFC, such as
biocompatibility and ability to absorb high contents
of water so as to retain a moist environment.15
Specifically, these basic properties of BC, in addition
to good permeability, resistance to degradation, and
low solubility, are advantageous for tissue regen-
eration, and they have been demonstrated in clin-
ical studies.16 In treatment of venous leg ulcers,
BC-based wound dressing was found to create a
moist, protective, and hypoxic environment for
wound healing.17 Further, application of BC wound
dressing to lower extremity ulcers have shown a
remarkably shorter time of wound closure in com-
parison to standard care.18 In another study, BC
wound dressing was evaluated as superior com-
pared with a standard wound care regarding pain
control, ease of use, and patient and nursing staff
satisfaction.19 BC is synthesized in pure form20 by
several bacterial species and has a similar chemical
structure compared with NFC. However, their
macromolecular properties differ, and BC has, for
example, not only higher crystallization21,22 but also
high fiber density that has been shown to limit cell
infiltration.23 In addition, introduction of functional
groups to enhance cell adhesion and biodegrad-
ability of the BC remains a challenge since microbial
fermentation conditions are limiting and, therefore,
restrict the introduction of many additive materials
required to control porosity and BC nanofiber
structure.20,24 CMC, on the other hand, is a cellulose
derivative containing a large number of carbox-
ymethyl groups on a cellulose backbone.25 However,
it requires crosslinking to form a hydrogel structure,
which often produces poisonous byproducts.26,27
CMC-based hydrofiber dressing has been intro-
duced as costly, more painful, and not easy to use
compared with other split-thickness skin graft do-
nor site dressings.28,29
We have previously shown that NFC-based
wound dressing is a promising material in clinical
use for skin graft donor site treatment as it provides
good attachment and adherence to the wound bed,
and smooth automatic detachment after skin re-
epithelialization.30 In this study, we aimed at eval-
uating more closely the effectiveness of NFC wound
dressing in skin graft donor site treatment com-
pared with a polylactide-based copolymer dressing,
which we use as a standard treatment. The copoly-
mer dressing is a synthetic and absorptive wound
dressing consisting of dl-lactide, e-caprolactone,
and trimethylene carbonate that offers instant
adaptability to the wound bed.31 Polylactids are a
class of biodegradable polyesters that have been
widely used in different biomedical applications due
to their biocompatibility.32 The structure of the co-
polymer dressing is highly porous, which enables
the moisture permeability and, thus, supports
wound healing and re-epithelization, hindering the
accumulation of wound exudate. Other advantages
of using the copolymer dressing in wound treatment
are its transparency and ability to detach from the
wound site as the wound heals.33
We hypothesized that the mean healing time of
wounds treated with NFC dressing would be com-
parable to wounds treated with the copolymer
dressing. Further, we speculated that NFC dressing
would serve as an effective wound dressing in donor
site care due to its one-time use, since it does not
require dressing changes, which, in turn, may also
reduce subjective pain experienced by the patient.34
CLINICAL PROBLEM ADDRESSED
Split-thickness skin grafting is a reconstructive
procedure that is most commonly used for manage-
ment of burn injuries. Skin harvesting creates a new
partial thickness wound, a donor site that causes
additional pain for the patient during the postoper-
ative recovery. Therefore, and because wound heal-
ing complications, such as delayed healing and
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infections, are common on donor sites, the donor sites
are problematic to treat. A dressing that would pro-
vide optimal healing, low costs, and minimal pain
with few dressing changes would be a preferred
choice for treatment of donor sites. This clinical study
intends to present the performance of a new wood-
derived NFC wound dressing as an effective dressing
in treatment of skin graft donor sites.
MATERIALS AND METHODS
Wound dressings
NFC wound dressing (FibDex) was kindly pro-
vided by UPM-Kymmene Corporation, Finland. The
dressing consists of non-woven fabric that is treated
with NFC on both sides. The manufacturing process
has been previously described.30 A commercially
available polylactic acid-based copolymer dressing
(Suprathel; Polymedics Innovations GmbH, Ger-
many) was used as a reference material.
In vitro cytotoxicity of nanofibrillar
cellulose dressing
The cytotoxic effect of NFC dressing was ana-
lyzed by using an XTT [(sodium-3¢-(lphenylamino-
carbonyl)-3,4-tetrazolium)-bis(4-methoxy-6-nitro)
benzensulfonic acid hydrate] test based on the
cleavage of the yellow tetrazolium salt XTT to form
an orange water-soluble formazan dye by dehy-
drogenase activity in active mitochondria. First, NFC
wound dressing was extracted under agitation for
24–2 h in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10% fetal bovine
serum (FBS) at 37–1C in compliance with the In-
ternational Organization for Standardization (ISO)
10993-5 and 10993-12. The absorption capacity of
NFC dressing was determined (25.6 mL extraction
medium/g test item) and considered for the extrac-
tion. The final weigh/volume ratio in the assay was
0.2 g/mL above the absorption capacity, which corre-
sponds to 100% extract concentration. As a negative
control, polypropylene (Greiner;Art.No.188.271, Lot-
No. E16053QH) was extracted at a weigh/volume ra-
tio of 1 g/5 mL medium. Latex Examination Gloves
(VWR; Lot 2014-06 29980031) were used as a positive
control and extracted at a surface/volume ratio of
6 cm2/mL of DMEM 10% FBS. A solvent control con-
sisting of extraction vehicle (DMEM 10% FBS; Euro-
fins Munich, Lot No. 17011 3HIe) alone was treated in
the same way as the treatment groups.
The cytotoxicity test was carried out with estab-
lished L929 cells (ATCC No. CCL-1, NCTC clone 929
[connective tissue mouse], male, age 100 days, clone
of strain L [DSMZ]) cultured in DMEM with 10%
FBS-Gold (PAA Laboratories GmbH) at 37–1C and
5.0% CO2. The extract of the NFC dressing and the
solvent control were diluted five times with DMEM
10% FBS at a ratio of 2:3, giving final concentrations
of 13.2%, 19.8%, 29.6%, 44.4%, 66.7%, and 100%. One
hundred microliters of the different dilutions or
100lL of the controls were pipetted into three par-
allel cultures in an empty 96-well plate (Greiner).
Subsequently, log-phase L929 cells were used for
preparation of a single-cell suspension at a density of
8.0·10 cells/mL. Fifty microliters of this cell sus-
pension were pipetted to a 96-well plate containing
the extracts with the exception of the blanks. The cell
culture plates were then incubated with the extracts
for 68–72 h at 37–1C, 5.0% CO2. Then, 1–2 h before
the end of the incubation period, 50lL of the XTT
labeling mixture (Roche Diagnostics; Cell Prolifera-
tion Kit II) was added to each well. The cells were
incubated for further 1–2 h, and the plate was sub-
sequently transferred to a microplate reader equip-
ped with a 490-nm filter to read the absorbance
(reference wavelength 630 nm).
Patients
The clinical study was performed according to the
Clinical Investigation of medical devices for human
subjects, good clinical practice (ISO 14155:2011) at
Helsinki Burn Centre, Helsinki University Hospi-
tal, Finland. The study was approved by the Re-
search Ethics Committee at the Helsinki University
Hospital (99/13/03/02/2014 and HUS/1166/2016),
and it enrolled burn patients or patients requiring
skin graft donor site treatment with exclusion cri-
teria of pregnancy and age younger than 18 or older
than 75 years. Subjects or their legal representa-
tives were informed of procedures and provided
written informed consent.
Surgical procedure
A Zimmer air dermatome (Zimmer, Inc.) was
used to harvest 6/1,000 inch (0.15 mm)–12/1,000 inch
(0.30 mm) thick split-thickness skin grafts. The sep-
arate donor sites were covered with NFC dressing or
with NFC and copolymer dressings as previously
described,30 except in one patient whose single donor
site was divided into two parts and treated with both
dressings. Experimental dressings that were left in
place for the entire treatment period were covered by
Jelonet (Smith and Nephew, United Kingdom) and
fixed with staples. When compared with the copoly-
mer dressing, anatomically equivalent areas were
chosen for donor sites. The dressings were randomly
selected for the treatment of each donor site.
Skin graft donor site treatment
and observations
The healing time of the donor site was deter-
mined as the self-detachment day of the NFC
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dressing or the copolymer dressing. Both donor site
materials behave similarly, detaching from the
wound bed when new epithelium is regenerated.
Postoperatively, the experimental dressings on
skin graft donor sites were checked by visual ob-
servation when changing the overlaying dress-
ings at an interval of a few days on average on
postoperative days (PODs) 4, 7, 10, 14, 20, and 28,
or when clinically relevant (–1–3 days), until self-
detachment. During observations, skin quality, the
epithelialization percentage of the donor site skin,
and the possible adverse effects were evaluated by
a plastic surgeon. In addition, subjective pain ex-
perience was questioned from the patients using
scale 0–10 (0 representing no pain and 10 the worst
possible pain). Donor sites and wound dressings
were photographed during the examinations
throughout the clinical study period. Skin elastic-
ity, viscoelasticity, and transepidermal water loss
(TEWL) were measured after discharge, 1 and 6
months postoperatively. In addition, scar quality
was evaluated by using the Patient and Observer
Scar Assessment Scale (POSAS) that was trans-
lated to Finnish but not validated in Finnish lan-
guage. The POSAS consists of two numerical
scales: the patient and the observer scar assess-
ment scale that scores six parameters on a 10-point
rating scale, in which the highest score represents
the worst imaginable scar.35,36
Non-invasive measurements
Elasticity, viscoelasticity, and TEWL were mea-
sured from patients’ epithelialized skin treated with
NFC or copolymer dressings during follow-up ex-
amination at 1 and 6 months after commencement
of the treatments using DermaLab Skinlab COM-
BO (Cortex Technology, Denmark), which is a reli-
able instrument for objective measurements of skin
elasticity and TEWL.37,38 The elasticity of the skin
was assessed in terms of elastic modulus and vis-
coelasticity. TEWL was expressed as g/m2/h to as-
sess the epidermal barrier function. TEWL
increases when the skin barrier is damaged and is,
therefore, an important parameter to evaluate the
efficiency of the human skin barrier. For measure-
ments, a single (in case of TEWL measurement) or
4–5 (in case of elasticity measurements) successive
readings were taken at the same site. Control
measurements were taken on healthy, not-operated
skin of the same subject at equal locations.
Statistical analysis
Normal distribution of the data was tested for each
parameter at each measurement point by
the Shapiro-Wilk Test. Significant differences be-
tween independent data were analyzed by using
Student’s t-test (normal distribution) or Mann-
Whitney U test (non-normal distribution) when
comparing two groups or using one-way analysis of
variance (normal distribution) or Kruskal-Wallis H
test (non-normal distribution) when comparing more
than two groups. Paired data were assessed by using
paired t-test (normal distribution) or the Wilcoxon
signed-ranks test (non-normal distribution). Values
of p<0.05 were considered statistically significant.
RESULTS
Cytotoxicity of NFC wound dressing
The cytotoxicity of the NFC wound dressing was
assessed by means of the XTT test using mouse cell
line L929. NFC wound dressing was extracted
under agitation, after which L929 cells were incu-
bated with the following end concentrations of the
extract: 13.2%, 19.8%, 29.6%, 44.4%, 66.7%, and
100%. The highest extract concentration corre-
sponds to the ISO 10993-5 and 10993-12 described
weight/volume ratio of 0.2 g/mL. The extraction
procedure did not reveal any abnormalities in the
extraction medium or the test item. No changes
regarding clarity, color, and presence or absence of
foreign material occurred in the extraction me-
dium. The pH-value of the test extract was 7.5
(solvent control pH 7.5).
The results showed no relevant reduction of cell
proliferation and/or cell viability. With the highest
extract concentration (100%), the dehydrogenase
activity was not reduced. Microscopically, no inhibi-
tion of cell growth and no cell lysis were observed at
all extract concentrations used. The controls con-
firmed the validity of the study. Between the solvent
control and the negative control, no relevant differ-
ence could be observed. The positive control showed a
distinct reduction in cell viability and cell prolifera-
tion, as dehydrogenase activity was reduced to 1%.
Patients’ characteristics and the study course
Progress through the study phases is presented
in Fig. 1 as a flow diagram. We enrolled a total of 24
patients (patient no. 11–34), with 19 completing
the full study course with NFC dressing treatment.
An intra-individual comparison of NFC and copol-
ymer dressings was performed in 17 patients. One
patient was deceased on POD 22 and results of 4
other patients are lacking from the study due to
failure to observe pain, POSAS, or the percentage
of re-epithelialization or failure to attend follow-up
appointments.
The baseline characteristics of all the enrolled
patients are presented in Table 1. The average age
of all the patients was 49 years –18, range 21–74
years. Majority of the patients were male (67%).
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The total body surface area varied from 1% to 50%.
Majority of the patients suffered from flame burns.
All the patients were Caucasian. The total size of
donor site(s) for a patient varied between 64 cm2 and
1,132 cm2 for the NFC dressing, and between
82.5 cm2 and 1,201 cm2 for the copolymer dressing.
Wound healing time and treatment
The healing time of the donor site was determined
as the self-detachment day of the dressing. The de-
tachment of NFC dressing is shown in Fig. 2. The
mean healing time (Fig. 3) for NFC dressing (N=24)
with independent samples was 18.5 (–5.3) days and
for the copolymer (N=16) it was the same 18.5 (–4.6)
days (p=0.86, Mann-Whitney U test). In pairwise
comparisons (N=16), the mean healing time for NFC
dressing was 18.3 (–5.7) days (p=0.59 compared with
copolymer, Wilcoxon signed-ranks test). Seven pa-
tients demonstrated the same healing time with both
dressings, and six patients treated with NFC dress-
ing showed 1–4 days shorter healing time compared
with the copolymer. Figure 4 shows an example of the
treatment of donor sites with NFC and copolymer
dressings during the postoperative period.
Adverse events observed during
or after the treatment
Adverse events were observed in five patients
treated with NFC dressing. Two of them were con-
sidered to be as a result of treatment with NFC
dressing; in these cases, the dressing had partially
slid off the donor site. The material was partly re-
placed with another dressing type. In comparison,
the copolymer dressing had partly slid off the donor
site in one patient. In two other patients, an infec-
tion was suspected on the donor site treated with
NFC dressing. In these cases, the NFC dressing was
partially replaced with other dressing. However,
Figure 1. Flow chart of the clinical study. A total of 24 patients were enrolled in the study and were treated with NFC dressing, whereas 17 patients had an
intra-individual comparison of NFC dressing and copolymer dressing. NFC, nanofibrillar cellulose; POSAS, Patient and Observer Scar Assessment Scale.
Table 1. Patient demographics and clinical characteristics
Characteristics NFC (N = 24) Copolymer (N = 17) p
Age, mean (SD) 49 (18) 49 (17) 1*
Gender F:M 8:16 4:13 —
TBSA (%), mean (SD) 16.5 (13.7) 20.0 (13.6) 0.42*
Etiology
Flame burn 15 (62%) 15 (88%) —
Scald burn 2 (8%) 0 (0%) —
Electrical burn 1 (4%) 0 (0%) —
Chemical injury 3 (13%) 0 (0%) —
Contact with hot object 3 (13%) 2 (12%) —
Comorbidities
Abundant alcohol consumption 5 (21%) 3 (18%) —
Asthma 3 (13%) 2 (12%) —
Diabetes 3 (13%) 2 (12%) —
Hypercholesterolemia 3 (13%) 1 (6%) —
Hypertension 6 (25%) 3 (18%) —
Obesity 4 (17%) 3 (18%) —
Smoking 3 (13%) 2 (12%) —
Location
Back 3 (13%) 3 (18%) —
Thigh 19 (79%) 13 (76%) —
Scalp 1 (4%) 0 (0%) —
Flank/stomach 1 (4%) 1 (6%) —
*Student’s t-test.
NFC, nanofibrillar cellulose; SD, standard deviation; TBSA, total body
surface area.
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due to the condition of the patient, it is difficult to
determine whether the infection occurred because
of NFC dressing treatment or other clinical influ-
encing factors. No infection occurred in the
copolymer-treated donor site. In one patient, an in-
fection was observed on both donor sites treated
with NFC dressing and copolymer dressing.
Device deficiencies for NFC dressing were re-
ported in two patients. In one, more hematoma for-
mation was observed at the donor site treated with
NFC dressing as compared with a similar donor site
treated with the copolymer dressing for the same
patient, but it did not cause any extra discomfort. For
the same patient, small skin breaks were identified
on the donor site treated with NFC dressing 1 month
post-surgery, whereas the donor site treated with the
copolymer dressing was intact. In one patient, the
edges of adjacent NFC dressings moved slightly away
from each other, thus revealing some wound surface,
which was covered with other dressing material.
After the treatment, that is, complete self-
detachment of the dressing, residual wounds were
observed in two patients treated with NFC dress-
ing and in one patient treated with the copolymer
dressing (Fig. 5).
Assessments regarding skin epithelialization,
pain, and scar characteristics
We observed no statistically significant differ-
ence in the percentage of epithelialization between
donor sites treated with NFC and copolymer dress-
ings at POD 14 (46.4–39.0% for NFC, 43.9–
40.0% for copolymer; p=0.72, paired-samples t-test,
N=11) or at 1 or 6 months post-surgery (N=13). At
1 month, donor site skin was not fully epithelialized
in all patients (99.3–1.2% for NFC, 99.5–0.8% for
copolymer; p=0.34, paired-samples t-test), whereas
at 6 months, 100% of each donor site was epithelia-
lized (Fig. 6).
When evaluating the pain experience of the pa-
tients during the treatment and the follow-up, pain
scores did not show any statistically significant
difference between skin graft donor sites treated
with the NFC dressing and those treated with the
copolymer dressing at any of time points evaluated,
even if there was a trend toward less pain in NFC
dressing-treated donor sites (Table 2). The results
of the translated but not validated POSAS re-
vealed a significant difference between NFC and
copolymer dressings for separate observations, in-
cluding thickness in the Observer score at 1 month
(p=0.04) and vascularity in the Observer score at 6
months (p=0.008), favoring NFC dressing (Supple-
mentary Table S1). No significant differences were
observed between NFC and copolymer dressings in
the overall opinions by the Observer or Patient scale
at 1 or 6 months (Table 2).
Scar quality measurements
Regarding the secondary outcomes measured
using DermaLab during the patient follow-up, the
paired data showed significantly smaller elasticity
values in the NFC dressing-treated donor sites
compared with the copolymer dressing-treated do-
nor sites at 1 month (N=14) with respect to both
viscoelasticity (13.7–3.4 MPa for NFC; 16.3–
5.3 MPa for copolymer; p=0.02, Wilcoxon signed-
Figure 3. Wound healing time in days presented as mean (standard deviation).
Indep., independent samples.
Figure 2. The detachment of NFC dressing from the donor site. (A) An experienced staff gently removes the dressing when the material is able to be
detached without breaking the newly formed skin. (B) The epithelialized skin graft donor site after detachment of NFC dressing.
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ranks test) and elastic modulus (5.5–1.0 MPa for
NFC; 6.2–1.6 MPa for copolymer; p=0.01, paired-
samples t-test) (Supplementary Fig. S1). However,
no statistically significant differences were found
between NFC and the copolymer dressing-treated
donor sites at 1 month (N=14) in terms of TEWL
(29.8–13.2 g/m2/h for NFC; 26.8–9.7 g/m2/h for
copolymer; p=0.36, paired-samples t-test) or at
6 months (N=12) in terms of viscoelasticity (12.4–
2.7 MPa for NFC; 12.9–3.1 MPa for copolymer;
Figure 4. Skin graft donor site treatment with NFC and copolymer dressings of patient 28. (A, B) The skin graft donor site in operation. A transparent NFC
dressing was placed on the left thigh (A), and white copolymer dressing was placed on the right thigh (B). (C, D) POD 2. Both dressings were dry and well
attached to the donor site. (E, F) POD 7. Dressings were still dry and attached. (G, H) POD 9. Small pieces of both dressings were detached from the edges. (I,
J) POD 14. Both dressings detached on the same day (POD 14), revealing an epithelialized donor site. (K, L) POD 21. One hundred percent of NFC dressing-
treated donor site was epithelialized, whereas the epithelialization percentage for the copolymer-treated donor site was 97%. POD, postoperative day.
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p=0.49, paired-samples t-test), elastic modulus
(5.1–0.8 MPa for NFC; 5.1–0.9 MPa for copolymer;
p=0.83, paired samples t-test), or TEWL (9.0–
5.4 g/m2/h for NFC; 11.2–7.4 g/m2/h for copolymer;
p=0.14, Wilcoxon signed-ranks test) in pairwise
comparison (Supplementary Fig. S1).
The values of TEWL and elastic modulus from
donor sites treated with NFC dressing and copol-
ymer dressing differed significantly from the val-
ues of the healthy skin at 1 month, whereas
viscoelasticity values at 1 month and all values at 6
months showed no differences between healthy
skin and NFC dressing or the copolymer dressing-
treated donor site skin (Supplementary Table S2).
When comparing values recorded at 1 and 6
months, a significant improvement was observed
with the NFC dressing regarding TEWL (p <0.001)
and with the copolymer dressing regarding TEWL
(p =0.01), viscoelasticity (p=0.04), and elastic
modulus (p= 0.047) between the time points (Sup-
plementary Table S2).
DISCUSSION
This study was designed to compare the effects of
NFC dressing on a synthetic polylactide-based co-
polymer dressing that is the most commonly used
material to treat large skin graft donor sites at our
burn center. In the treatment of skin graft donor
sites, NFC dressing was found to provide equal
wound healing time and epithelialization com-
pared with the copolymer dressing. Importantly,
however, the elasticity of epithelialized donor site
skin was improved after treatment with NFC
dressing, whereas no difference regarding TEWL
was observed between NFC dressing and the co-
polymer dressing-treated donor sites. Further, scar
quality assessed by using the translated but not
validated POSAS suggested some advances in the
use of NFC dressing over the copolymer dressing.
In light of the fact that split-thickness skin
grafting can cause excess pain for the patient, sev-
eral studies have shown the copolymer dressing to
Figure 5. Skin graft donor sites after the treatment with NFC dressing on the left thigh (A) and the copolymer dressing on the right thigh (B) on the same
patient on POD 28 after the detachment of the dressings (NFC on POD 15, copolymer on POD 17). Residual wounds were found on both donor sites.
Figure 6. Epithelialization of the donor site skin at 1 and 6 months after treatment with NFC dressing and copolymer dressing.
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decrease pain scores in patients compared with
other wound dressings.31,33,39,40 According to our
results, pain scores reported for NFC dressing are
similar to those reported for the copolymer dressing.
With regard to in vitro cytotoxicity testing, no
particles in cytotoxic concentrations were re-
leased from NFC wound dressing under the given
conditions used in this study, and as has been
previously stated.30 During or after the treatment
with NFC dressing, no major adverse events or
allergic reactions were detected. In addition, no
life-threatening complications were observed
during the study. Wound healing is a complex pro-
cess where the maturation of the skin after
wound closure occurs slowly. The newly formed re-
epithelialized skin is fragile and sensitive to me-
chanical interaction, and it may therefore easily
break. In our study, superficial skin lesions, de-
scribed as residual wounds, were observed in some
patients after epithelialization of donor sites treated
with both NFC dressing and copolymer dressing. In
clinical use, NFC dressing is performed as a pliable
wound dressing that adheres well to the wound bed.
The wound healing time was determined as the
self-detachment day of the material, but the exact
time for full epithelialization cannot be stated due
to the nature of NFC dressing. During treatment,
NFC dressing was covered by other dressings that
kept it in place. NFC dressing was gently removed
during the visual observation by experienced staff
but only when the material was able to be detached
without breaking the newly formed skin. In some
patients, NFC dressing was removed piece by piece
over several days, so that majority of the donor site
had epithelialized whereas small pieces of the
dressing were still attached. An equal procedure
was used for the copolymer dressing. Therefore,
epithelialization may have occurred before the fi-
nal detachment of the material, which might ex-
plain the long healing times detected in this study
compared with others.41,42 Further, wound healing
time is affected by different comorbidities, such as
abundant alcohol consumption, diabetes mellitus,
obesity, or smoking, which impair the wound
healing process.43 In this study, the majority of the
enrolled patients suffered from one or more co-
morbidities.
The skin forms a protective barrier against
pathogens, and an open wound always bears the
risk of an infection. Wound infections observed
during this study were not considered to be related
to the use of NFC dressing. According to our re-
sults, use of NFC dressing does not appear to bear
any more risk for infections than the copolymer
dressing. Risk of infection may be enhanced in do-
nor sites located in certain anatomical areas, or due
to comorbidities of the patient.43 For the same
reasons, and without a prominent infection, a
wound may secrete an excessive amount of exudate
that induces the detachment of the wound dress-
ing. During the course of this study, this phenom-
enon was observed with both dressings.
One important aspect in wound treatment is the
cost-effectiveness. The copolymer dressing has been
rated as an expensive material compared with most
of those used for treatment of skin graft donor
sites31,40 and its acquisition costs are also quite
high.44 NFC dressing is not yet commercially avail-
able, so the cost of a dressing has yet to be deter-
mined. However, consideration should be given to
the fact that NFC dressing is produced from natural
sustainable raw materials and it does not break
down in the wound. In addition, it can be tuned to
demand and manufactured in large sheets, a signif-
icant advantage over other dressings, which are of-
ten restricted to a maximum size due to their
production process. Having bigger dressing sizes
available makes treatment of extensive donor sites
and wounds easier, as they may be covered by one
dressing instead of several smaller dressings.
Regarding storage, NFC dressing is stored at
room temperature (RT) and atmosphere, whereas
the copolymer dressing requires storage in a re-
frigerator due to hydrolysis that may occur at RT.
Other wound dressings may require even more
specific storage conditions or additional materi-
als for storage, such as storing in salt solution or
in foil. Compared with these dressings, NFC
dressing offered as a dry dressing is more eco-
Table 2. Results of the pain score and the Patient
and Observer Scar Assessment Scale
POD 10–15 1 Month 6 Months
Pain
NFC (N = 11) 0.55 (0.9) 0.82 (1.8) 0.27 (0.5)
copolymer (N= 11) 1.18 (2.2) 1.18 (1.8) 0.45 (0.9)
p 0.34* 0.17* 0.34*
POSAS observer score,a overall opinion
NFC (N = 13) — 2.81 (0.8) 2.19 (0.7)
copolymer (N= 13) — 2.85 (0.8) 2.31 (0.6)
p — 0.66** 0.24**
POSAS patient score,a overall opinion
NFC (N = 13) — 5.15 (2.9) 3.00 (1.6)b
copolymer (N= 13) — 4.92 (3.0) 3.58 (2.2)b
p — 0.47** 0.18**
Values are presented as mean (SD).
aPOSAS translated to Finnish, but not validated in Finnish language.
bN = 12, scores of 1 patient are lacking.
*Student’s t-test.
**Wilcoxon signed-ranks test.
N, number of patients; POD, postoperative day; POSAS, Patient and
Observer Scar Assessment Scale.
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logical and does not require a cold chain
for transportation.
The use of NFC in a wound dressing
may allow modification and functionali-
zation of the dressing, for example, by
introducing drug molecules or proteins,
thereby offering a wide variety of affor-
dances for NFC dressing. Often, ionic
silver is added in wound dressings, such
as in BC- or CMC-based dressings, to in-
duce antimicrobial properties.16,27,45–47
However, silver has been shown to have
cytotoxic effects on cells.48 Recently, in contrast,
Powell et al.14 showed that NFC originating from
wood was able to inhibit bacterial growth, sug-
gesting inherent anti-microbial properties of NFC.
These properties would serve as an advanced fea-
ture for a wound dressing.
INNOVATION
Skin graft donor site management requires
special consideration, but no dressing type exists
that is superior over other types of dressings re-
garding optimal healing. In this clinical study,
the performance of NFC dressing was shown to
be comparable to or even better than the refer-
ence copolymer dressing. NFC dressing is a to-
tally new dressing created from wood-based
material that is free from animal or human con-
stituents, is safe to use, appears suitable for skin
graft donor site treatment, and may result in
better scar quality. Therefore, NFC dressing can
be considered a promising material for future
clinical applications.
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KEY FINDINGS
 NFC dressing as treatment for skin graft donor sites performs compa-
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ABBREVIATIONS
AND ACRONYMS
BC ¼ bacterial cellulose
CMC ¼ carboxymethyl cellulose
DMEM ¼ Dulbecco’s modified Eagle’s
medium
FBS ¼ fetal bovine serum
ISO ¼ International Organization
for Standardization
NFC ¼ nanofibrillar cellulose
POD ¼ postoperative day
POSAS ¼ Patient and Observer
Scar Assessment Scale
TEWL ¼ transepidermal water loss
XTT ¼ sodium-3¢-(lphenylaminocarbonyl)-
3,4-tetrazolium)-bis(4-methoxy-6-
nitro) benzensulfonic acid hydrate
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